I agree that this site is using cookies. You can find further informations here.
X
Pous, A. Font
38  results:
Search for persons X
?
1

Surgical outcome of pre-operative atezolizumab before radic..:

Szabados, B. ; Duran, I. ; Crabb, S.J....
European Urology Supplements.  18 (2019)  1 - p. e1516 , 2019
Link: https://doi.org/10.1016/..
 
?
2

Baseline clinicopathological features as predictive markers..:

Font, Pous A.
European Urology Supplements.  15 (2016)  13 - p. e1712 , 2016
Link: https://doi.org/10.1016/..
 
?
3

Impact of new therapies in the treatment of metastatic Cast..:

Font, Pous A. ; Piulats, J. ; Etxaniz, O....
European Urology Supplements.  15 (2016)  13 - p. e1668 , 2016
Link: https://doi.org/10.1016/..
 
?
4

2635 MAJA trial: maintenance vinflunine post cisplatin chem..:

Jiménez, J. Garcia Donas ; Valderrama, B. Pérez ; Pous, A. Font...
European Journal of Cancer.  51 (2015)  - p. S524-S525 , 2015
Link: https://doi.org/10.1016/..
 
?
5

543 BRCA1 MRNA EXPRESSION IN PATIENTS WITH BLADDER CANCER T..:

Gago Ramos, J.L. ; Font Pous, A. ; Ibarz Servio, L....
European Urology Supplements.  8 (2009)  4 - p. 256 , 2009
Link: https://doi.org/10.1016/..
 
?
6

Multimodal treatment for squamous cell carcinoma of the eso..:

Pous, A. Font ; Llamazares, J. Fernández ; Tolivar, A. Arellano...
Revista de Oncología.  3 (2001)  3 - p. 142-150 , 2001
Link: https://doi.org/10.1007/..
 
?
7

SEOM clinical guidelines for the treatment of small-cell lu..:

SEOM Guidelines Working Group ; Artal Cortés, Ángel ; Dómine Gómez, Manuel...
Clinical and Translational Oncology.  12 (2010)  1 - p. 27-31 , 2010
Link: https://doi.org/10.1007/..
 
?
8

Risk Management Plans: are they a tool for improving drug s..:

Frau, Serena ; Font Pous, Maria ; Luppino, Maria Rosa.
European Journal of Clinical Pharmacology.  66 (2010)  8 - p. 785-790 , 2010
Link: https://doi.org/10.1007/..
 
?
9

La regulación de los medicamentos: teoría y práctica:

Zara Yahni, C. ; Segú Tolsa, L. ; Font Pous, M..
Gaceta Sanitaria.  12 (1998)  1 - p. 39-49 , 1998
Link: https://doi.org/10.1016/..
 
?
10

Publisher Correction: Clinical efficacy and biomarker analy..:

Powles, Thomas ; Kockx, Mark ; Rodriguez-Vida, Alejo...
Nature Medicine.  29 (2023)  12 - p. 3271-3271 , 2023
Link: https://doi.org/10.1038/..
 
?
11

Final Results of Neoadjuvant Atezolizumab in Cisplatin-inel..:

Szabados, Bernadett ; Kockx, Mark ; Assaf, Zoe June...
European Urology.  82 (2022)  2 - p. 212-222 , 2022
Link: https://doi.org/10.1016/..
 
?
12

Toxicity and Surgical Complication Rates of Neoadjuvant Ate..:

Szabados, Bernadett ; Rodriguez-Vida, Alejo ; Durán, Ignacio...
European Urology Oncology.  4 (2021)  3 - p. 456-463 , 2021
Link: https://doi.org/10.1016/..
 
?
13

Final Overall Survival Analysis of the SOGUG Phase 2 MAJA S..:

Bellmunt Molins, Joaquim ; García-Donas Jiménez, Jesús ; Valderrama, Begoña P....
Clinical Genitourinary Cancer.  18 (2020)  6 - p. 452-460 , 2020
Link: https://doi.org/10.1016/..
 
?
14

Factores asociados a la prescripción de medicamentos:

Catalán Ramos, Aránzazu ; Madridejos Mora, Rosa ; Font i Pous, Maria...
Gaceta Sanitaria.  3 (1989)  14 - p. 497-501 , 1989
Link: https://doi.org/10.1016/..
 
?
15

Drug information by public health and regulatory institutio..:

Formoso, Giulio ; Font-Pous, Maria ; Ludwig, Wolf-Dieter...
Health Policy.  121 (2017)  3 - p. 257-264 , 2017
Link: https://doi.org/10.1016/..
 
1-15